Acrivon Therapeutics (ACRV) CAO awarded 14,227 RSUs in equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Peterson Katharine reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics, Inc. reported that Chief Accounting Officer Katharine Peterson received a grant of 14,227 shares of Common Stock on May 18, 2026, at a stated price of $0.00 per share. According to the footnote, these shares are in the form of restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock.

Of these RSUs, 16.67% are scheduled to vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments afterward, subject to her continuous service through each vesting date. Following this award, Peterson directly holds 18,134 shares of Common Stock as reported in the filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Katharine

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	14,227	$0.00	--

Holdings After Transaction: Common Stock — 18,134 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 14,227 shares Grant price: $0.00 per share Shares after transaction: 18,134 shares +2 more

5 metrics

RSUs granted 14,227 shares Restricted stock unit award on May 18, 2026

Grant price $0.00 per share Stated price for RSU grant

Shares after transaction 18,134 shares Direct Common Stock holdings following grant

Initial vesting portion 16.67% of RSUs Vesting on November 18, 2026

Remaining vesting schedule 10 quarterly installments Balance of RSUs vest after November 18, 2026

Key Terms

restricted stock units ("RSUs"), contingent right, vest, continuous service

4 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vest financial

"16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continuous service financial

"in each case subject to the Reporting Person's continuous service through each such vesting date."

Form 4 Insider Transactions: What Each Field Means →

05/20/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last)

(First)

(Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A⁽¹⁾		14,227	A	$0	18,134	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Katharine Peterson?

Acrivon reported that Chief Accounting Officer Katharine Peterson received a grant of 14,227 restricted stock units of Common Stock. These RSUs were awarded at a stated price of $0.00 per share as part of her equity compensation, increasing her direct holdings to 18,134 shares.

How many Acrivon (ACRV) shares does Katharine Peterson hold after this Form 4 transaction?

After the reported RSU grant, Katharine Peterson is shown holding 18,134 shares of Acrivon Common Stock. This figure reflects her direct ownership position immediately following the award as disclosed in the Form 4 filing, combining existing holdings with the newly granted restricted stock units.

What are the vesting terms of Katharine Peterson’s Acrivon (ACRV) RSU grant?

The RSU grant vests over time. 16.67% of the restricted stock units are scheduled to vest on November 18, 2026. The remaining RSUs will then vest in 10 substantially equal quarterly installments, provided she maintains continuous service through each vesting date.

What does each restricted stock unit (RSU) in Acrivon (ACRV) represent for this grant?

Each RSU in this grant represents a contingent right to receive one share of Acrivon’s Common Stock. The units do not convert into shares until they vest, and vesting depends on Katharine Peterson’s continued service with the company through specified future dates.

Is Katharine Peterson’s Acrivon (ACRV) Form 4 transaction a market purchase or sale?

The transaction is a grant or award acquisition, not a market purchase or sale. It is reported under transaction code "A" and reflects equity compensation awarded at a stated price of $0.00 per share, rather than an open-market trade in Acrivon stock.